Tumour associated vasculature-on-a-chip for the evaluation of microbubble-mediated delivery of targeted liposomes

Bourn, Matthew; Mohajerani, Safoura Zahed; Mavria, Georgia; Ingram, Nicola; Coletta, P. Louise; Evans, Stephen D.; Peyman, Sally A.

doi:10.1039/d2lc00963c

Cited by 7 publications

(6 citation statements)

References 72 publications

(115 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Integrin expression and interactions with RGD peptides may change between cell lines and subtypes. HCT116, HT‐29, SW620, Caco‐2, LoVo, LS174T, DLD‐1, SW480, and Colo205 colorectal cancer cell lines contain integrin αvβ3, which can interact with RGD peptides 234,238 . The RKO cell line has been demonstrated to interact with RGD peptides, which can attach to integrin αvβ5 239,240 …”

Section: The Rgd Peptide In Cancer Targetingmentioning

confidence: 99%

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

Javid,

Oryani,

Rezagholinejad

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

RGD peptide can be found in cell adhesion and signaling proteins, such as fibronectin, vitronectin, and fibrinogen. RGD peptides' principal function is to facilitate cell adhesion by interacting with integrin receptors on the cell surface. They have been intensively researched for use in biotechnology and medicine, including incorporation into biomaterials, conjugation to medicinal molecules or nanoparticles, and labeling with imaging agents. RGD peptides can be utilized to specifically target cancer cells and the tumor vasculature by engaging with these integrins, improving drug delivery efficiency and minimizing adverse effects on healthy tissues. RGD‐functionalized drug carriers are a viable option for cancer therapy as this focused approach has demonstrated promise in the future. Writing a review on the RGD peptide can significantly influence how drugs are developed in the future by improving our understanding of the peptide, finding knowledge gaps, fostering innovation, and making drug design easier.

show abstract

Section: The Rgd Peptide In Cancer Targetingmentioning

confidence: 99%

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

Javid,

Oryani,

Rezagholinejad

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…The treatment of exosomes carrying microRNA showed decreased cancer cell invasion (white arrows) as well as inhibition of the endothelial reorganization into tubular constructs [ 72 ]. C Liposomes were loaded in microbubbles that were collapsed using inertial cavitation induced by ultrasound in the vascular bed, enabling the deposition of the liposomes [ 112 ] …”

Section: Drug Delivery Development Based On Vascularized Tumor Modelsmentioning

confidence: 99%

“…They showed that this microRNA substantially curbed cancer migration, as well as angiogenesis by suppressing VEGF-A and VEGFR2 expression. An ingenious DDS used microbubbles to deliver loaded liposomes at the tumor site, combined with ultrasound both to permeabilize cell membranes and to make microbubbles collapse to release their content [ 112 ] (Fig. 5 C).…”

Section: Drug Delivery Development Based On Vascularized Tumor Modelsmentioning

confidence: 99%

Vascularized tumor models for the evaluation of drug delivery systems: a paradigm shift

Lopez-Vince,

Wilhelm,

Simon-Yarza

2024

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

As the conversion rate of preclinical studies for cancer treatment is low, user-friendly models that mimic the pathological microenvironment and drug intake with high throughput are scarce. Animal models are key, but an alternative to reduce their use would be valuable. Vascularized tumor-on-chip models combine great versatility with scalable throughput and are easy to use. Several strategies to integrate both tumor and vascular compartments have been developed, but few have been used to assess drug delivery. Permeability, intra/extravasation, and free drug circulation are often evaluated, but imperfectly recapitulate the processes at stake. Indeed, tumor targeting and chemoresistance bypass must be investigated to design promising cancer therapeutics. In vitro models that would help the development of drug delivery systems (DDS) are thus needed. They would allow selecting good candidates before animal studies based on rational criteria such as drug accumulation, diffusion in the tumor, and potency, as well as absence of side damage. In this review, we focus on vascularized tumor models. First, we detail their fabrication, and especially the materials, cell types, and coculture used. Then, the different strategies of vascularization are described along with their classical applications in intra/extravasation or free drug assessment. Finally, current trends in DDS for cancer are discussed with an overview of the current efforts in the domain. Graphical Abstract

show abstract

“…As a result, αvβ3 holds promise as a therapeutic target for cancer treatment. 59 Additionally, the vascularized tumor microfluidic chip platform can be utilized to investigate the impact of stromal cells on tumor cell attachment and growth, as well as the effects of tumor cells on blood vessel and mesothelium permeability in early and late metastasis models. 60 To better replicate the interaction between cancer cells and the tumor environment and enhance the prognosis of neuroblastoma, the Michael research team has designed a microvascular neuroblastoma tumor environment chip.…”

Section: ■ Organs-on-chipsmentioning

confidence: 99%

From Organ-on-a-Chip to Human-on-a-Chip: A Review of Research Progress and Latest Applications

Huang,

Liu,

Huang

et al. 2024

ACS Sens.

View full text Add to dashboard Cite

Organ-on-a-Chip (OOC) technology, which emulates the physiological environment and functionality of human organs on a microfluidic chip, is undergoing significant technological advancements. Despite its rapid evolution, this technology is also facing notable challenges, such as the lack of vascularization, the development of multiorgan-on-a-chip systems, and the replication of the human body on a single chip. The progress of microfluidic technology has played a crucial role in steering OOC toward mimicking the human microenvironment, including vascularization, microenvironment replication, and the development of multiorgan microphysiological systems. Additionally, advancements in detection, analysis, and organoid imaging technologies have enhanced the functionality and efficiency of Organs-on-Chips (OOCs). In particular, the integration of artificial intelligence has revolutionized organoid imaging, significantly enhancing high-throughput drug screening. Consequently, this review covers the research progress of OOC toward Human-on-achip, the integration of sensors in OOCs, and the latest applications of organoid imaging technologies in the biomedical field.

show abstract

Tumour associated vasculature-on-a-chip for the evaluation of microbubble-mediated delivery of targeted liposomes

Abstract: The vascular system is the primary route for the delivery of therapeutic drugs throughout the body and is an important barrier at the region of disease interest, such as a...

Cited by 7 publications

References 72 publications

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

Vascularized tumor models for the evaluation of drug delivery systems: a paradigm shift

From Organ-on-a-Chip to Human-on-a-Chip: A Review of Research Progress and Latest Applications

Contact Info

Product

Resources

About